Cingulate Inc., was incorporated in Delaware on December 14, 2012. The Company is a biopharmaceutical company leveraging its proprietary Precise Timed Release Drug Delivery Platform to develop next-generation products for Attention Deficit Hyperactivity Disorder and Anxiety Disorders. Its lead drug candidates CTx-1301 and CTx-1302 are intended as once-daily stimulant drugs for ADHD, while CTx-2103, a once-daily formulation of buspirone, is also being developed for the treatment of anxiety disorders. 

CING

CING Profile